Polycyclo Ring System Which Contains The Hetero Ring As One Of The Cyclos Patents (Class 540/468)
-
Publication number: 20040034004Abstract: The invention relates to certain bicyclic heterocycles havng the structure shown below which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, and atherosclerosis.Type: ApplicationFiled: March 6, 2003Publication date: February 19, 2004Inventors: Magnus Pfahl, Catherine Tachdjian, Hussien A. Al-Shamma, Andrea Fanjul Giachino, Karine Jakubowicz-Jaillardon, Jianhua Guo, Richard M. Fine, Lyle W. Spruce, James W. Zapf
-
Patent number: 6667302Abstract: The invention provides compounds of formula I: wherein R1 to R5 have any of the values defined in the specification, as well as pharmaceutically acceptable salts of the compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds, compositions, or salts to treat cancer. In embodiments, R4 and R5 taken together can be a 3, 4, or 5 membered saturated or unsaturated chain comprising members selected from the group consisting of non-peroxide oxygen, sulfur, N(X), and carbon, optionally substituted by oxo; wherein each X is independently absent or is H, 0, (C1-C4)alkyl, phenyl or benzyl; and wherein at least one of the chain members is an N—H group.Type: GrantFiled: June 13, 2001Date of Patent: December 23, 2003Assignee: Rutgers, The State University of New JerseyInventors: Edmond J. La Voie, Jung Sun Kim, Leroy Fong Liu
-
Patent number: 6656930Abstract: Certain aralkyl diazabicycloalkyl compounds are disclosed for treatment of CNS disorders, such as cerebral ischemia, psychosis, and convulsions.Type: GrantFiled: September 4, 2001Date of Patent: December 2, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Wayne D Bowen, Brian R. de Costa, Celia Dominguez, Xiao-Shu He, Kenner C. Rice
-
Patent number: 6653469Abstract: Taught is a process for purifying a benzoquinoid ansamycin antibiotic such as geldanamycin through the use of a fluid comprising supercritical carbon dioxide. In certain embodiments the fluid also includes an aliphatic alcohol such as methanol or ethanol.Type: GrantFiled: June 20, 2002Date of Patent: November 25, 2003Assignee: Murty Pharmaceuticals, Inc.Inventor: Murty Mangena
-
Patent number: 6605599Abstract: The present invention relates to epothilone derivatives, having the following formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1-R7 are as defined herein, methods for the preparation of the derivatives and intermediates thereof.Type: GrantFiled: May 26, 1998Date of Patent: August 12, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Gregory D. Vite, Soong-Hoon Kim, Robert M. Borzilleri, James A. Johnson
-
Publication number: 20030125366Abstract: Synthetic Phorboxazole A and derivatives thereof for the treatment of cancer, including inhibition of cancer cell growth, induction of apoptosis, and inhibition of metastises.Type: ApplicationFiled: May 14, 2002Publication date: July 3, 2003Applicant: Parker Hughes InstituteInventors: Fatih M. Uckun, Rama K. Narla, Craig Forsyth, Chi Sing Lee, Feryan Ahmed, Russel Drew Cink
-
Publication number: 20030096989Abstract: A method of making chlorins comprises the steps of reacting (e.g. condensing) a dipyrrin western half intermediate with an eastern half intermediate to form a tetrahydrobilene, and then cyclizing the tetrahydrobilene to form a chlorin. Intermediates including tetrahydrobilenes useful in such reactions are also described.Type: ApplicationFiled: May 8, 2002Publication date: May 22, 2003Inventors: Jonathan S. Lindsey, Masahiko Taniguchi, Doyoung Ra, Guoning Mo, Thiagarajan Balasubramanian
-
Patent number: 6566385Abstract: The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.Type: GrantFiled: January 9, 2001Date of Patent: May 20, 2003Assignee: Merck & Co., Inc.Inventors: S. Jane deSolms, Gerald E. Stokker, Anthony W. Shaw
-
Publication number: 20030069416Abstract: This invention relates to cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives that bind with high selectively and/or high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in the treatment of central nervous system (CNS) diseases. This invention also relates to the use of these cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the detection of GABAA receptors in tissue samples.Type: ApplicationFiled: April 24, 2002Publication date: April 10, 2003Applicant: Pfizer Inc.Inventors: Daniel Yohannes, George Maynard, Xiaojun Liu
-
Patent number: 6544974Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described. Preferred (R)-Chiral 1-Substitutedamino(n+1)-Alkanol compounds are substituted (R)-Chiral fused heterocyclic amino compounds.Type: GrantFiled: December 12, 2001Date of Patent: April 8, 2003Assignee: G.D. Searle & Co.Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
-
Patent number: 6545038Abstract: The invention provides compounds of formula as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhibitors of metalloproteases. Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.Type: GrantFiled: November 6, 2000Date of Patent: April 8, 2003Assignee: The Procter & Gamble CompanyInventors: Biswanath De, Stanislaw Pikul, Menyan Cheng, Neil Gregory Almstead, Randall Stryker Matthews, Michael George Natchus, Yetunde Olabisi Taiwo
-
Publication number: 20020164616Abstract: The invention describes crown ether chelators, including crown ethers having the formula 1Type: ApplicationFiled: December 19, 2001Publication date: November 7, 2002Applicant: Molecular Probes, Inc.Inventors: Vladimir V. Martin, Kyle R. Gee, Richard P. Haugland, Zhenjun Diwu
-
Patent number: 6455519Abstract: The invention relates to use of substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N- disubstituted fused-heterocyclo amines.Type: GrantFiled: November 15, 2001Date of Patent: September 24, 2002Assignee: G.D. SEarle & Co.Inventors: James A. Sikorski, Richard C. Durley, Deborah A. Mischke, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Margaret L. Grapperhaus, Brian S. Hickory, Mark A. Massa, Monica B. Norton, William F. Vernier, Barry L. Parnas, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
-
Patent number: 6429205Abstract: This invention relates generally to nitrogen containing heterobicycles of formulas A and B: which are inhibitors of trypsin-like serine protease enzymes, especially factor Xa, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.Type: GrantFiled: July 13, 2000Date of Patent: August 6, 2002Assignee: Bristol-Meyers Squibb Pharma CompanyInventors: Irina C. Jacobson, Mimi L. Quan
-
Patent number: 6417180Abstract: The invention relates to antimicrobial compounds which interact with zinc in a zinc finger of a bacterial DNA polymerase, methods of screening for such compounds, and methods of using such compounds to inhibit polymerase activity or bacterial growth.Type: GrantFiled: October 7, 1998Date of Patent: July 9, 2002Assignee: University of MassachusettsInventors: Neal C. Brown, Marjorie H. Barnes, George E. Wright
-
Patent number: 6410534Abstract: The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.Type: GrantFiled: June 29, 1999Date of Patent: June 25, 2002Assignee: Merck & Co., Inc.Inventors: Christopher J. Dinsmore, Ian M. Bell, Douglas C. Beshore, Theresa M. Williams
-
Patent number: 6372733Abstract: Disclosed herein are compounds of Formula I and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation.Type: GrantFiled: January 4, 2000Date of Patent: April 16, 2002Assignee: Merck & Co., Inc.Inventors: Charles G. Caldwell, Malcolm Maccoss, William K. Hagmann, Shrenik K. Shah, Kothandaraman Shankaran, Karla L. Furman
-
Publication number: 20020040017Abstract: A pyrrolesulfonamide derivative having the following formula (I): 1Type: ApplicationFiled: June 4, 2001Publication date: April 4, 2002Applicant: SUNTORY LIMITEDInventors: Akira Mizuno, Makoto Shibata, Tomoe Kamei, Harukazu Fukami, Norio Inomata
-
Patent number: 6359130Abstract: The present invention is directed to novel fused aryl and heteroaryl bridged indenopyrrolocarbazoles which are useful, inter alia, as therapeutic agents. The invention is also directed to methods for making and using the bridged indenopyrrolocarbazoles.Type: GrantFiled: May 17, 2000Date of Patent: March 19, 2002Assignee: Cephalon, Inc.Inventors: Jasbir Singh, Robert L. Hudkins, John P. Mallamo, Theodore L. Underiner, Rabindranath Tripathy
-
Patent number: 6358985Abstract: The present invention is directed to peptidomimetic macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.Type: GrantFiled: June 29, 1999Date of Patent: March 19, 2002Assignee: Merck & Co., Inc.Inventors: Neville J. Anthony, Ian M. Bell, Douglas C. Beshore, Terrence M. Ciccarone, S. Jane de Solms, Christopher J. Dinsmore, Gerald E. Stokker
-
Patent number: 6350545Abstract: Novel sulfonylinide and sulfonylmethide compounds are described which are useful as conductive salts. Also described is the use of the above compounds in salt form in battery electrolytes, particular salts having mixed perfluorocaron and hydrocarbon groups or having all hydrocarbon groups. The above salts are less expensive to produce and still exhibit excellent conductivity and low corrosivity.Type: GrantFiled: August 25, 1998Date of Patent: February 26, 2002Assignee: 3M Innovative Properties CompanyInventors: Alan David Fanta, Phat tan Pham, Steven Joseph Hamrock
-
Publication number: 20010056088Abstract: Hydroxamic acids having the formula 1Type: ApplicationFiled: June 14, 2001Publication date: December 27, 2001Applicant: American Cyanamid CompanyInventors: Jeremy I. Levin, James M. Chen
-
Publication number: 20010046982Abstract: Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into ophthalmic solutions and topically applied for the treatment of the increased intraocular pressure caused by glaucoma and the reduction of ocular hypertension.Type: ApplicationFiled: February 1, 2001Publication date: November 29, 2001Inventors: Kirk M. Maxey, Michelle L. Stanton
-
Patent number: 6274619Abstract: A compound of the formula: in which R1 is hydrogen, optionally substituted lower alkylcarbamoyl(lower)alkylidene, lower alkylidene, lower alkyl, optionally substituted ar(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, protected carboxy(lower)alkyl, carboxy(lower)alkyl, hydroxy(lower)alkyl, optionally substituted lower alkylcarbamoyl(lower)alkyl, lower alkylthio(lower)alkyl, carboxy(lower)alkanoyl, protected carboxy(lower)alkanoyl, aroyl, lower alkanoyl, or optionally substituted arylcarbamoyl(lower)alkyl, R2 is hydrogen, carboxy, protected carboxy, formyl or N-(lower)alkyl-N-(lower)alkoxycarbamoyl, R3 is hydrogen or amidino-protective group, A is lower alkylene or carbonyl, X is Y is lower alkylene, —S— or —SO2—, Z is —S— or —O—, and the line: is a single bond or a double bond, or pharmaceutically acceptable salts thereof, which is useful as a medicament.Type: GrantFiled: May 31, 2000Date of Patent: August 14, 2001Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Akito Tanaka, Hiroaki Mizuno, Minoru Sakurai
-
Patent number: 6211359Abstract: The invention relates to a triaza-cryptand of the general Formula I wherein a is selected from the group consisting of 0 and 1, b and c independently are selected from the group consisting of 0 and 1, with the proviso that not both of b and c are 0, d is selected from the group consisting of 1, 2 and 3, e and f independently are selected from the group consisting of 0 and 1, with the proviso that not both of e and f are 0, R1 and R2 are either hydrogen or form an alkyl(C1-C4) benzene ring or an alkoxy(C1C4) benzene ring together with C1 and C2, wherein C2 is the para position, R3 and R2 are either hydrogen or form an alkyl(C1-C4) benzene ring or an alkoxy(C1-C4) benzene ring together with C3 and C4, wherein C3 is the para position, R5 and R6 are either hydrogen or form a benzene ring or a naphtalene ring together with C5 and C6, R7 and R8 are either hydrogen or form an alkyl(C1-C4) benzene ring or an alkoxy(C1-C4) benzene ring together with C7 and C8, wherein C8 is the para position,Type: GrantFiled: August 17, 1999Date of Patent: April 3, 2001Assignee: AVL Medical InstrumentsInventors: Huarui He, Mark Alan Mortellaro, Marco Jean Pierre Leiner
-
Patent number: 6156282Abstract: The invention relates to new calixarenes of formula: ##STR1## in which R.sup.1 represents a crown ether chain that includes at least two aryl or cycloalkyl rings,R.sup.2 is a hydroxyl or alkoxy group, or the two R.sup.2 groups together form a crown ether chain such as R.sup.1, and R.sup.3 represents a hydrogen atom or an alkyl group. The calixarenes are used to selectively extract caesium from aqueous solutions that notably have high concentrations of sodium.Type: GrantFiled: January 27, 1999Date of Patent: December 5, 2000Assignee: Commissariat a l'Energie AtomiqueInventors: Jean-Fran.cedilla.ois Dozol, Veronique Lamare, Christophe Bressot, Rocco Ungaro, Alessandro Casnati, Jacques Vicens, Zouhair Asfari
-
Patent number: 6103723Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.Type: GrantFiled: October 13, 1998Date of Patent: August 15, 2000Assignee: Merck & Co., Inc.Inventors: Jeffrey M. Bergman, Christopher J. Dinsmore, Samuel L. Graham
-
Patent number: 6093710Abstract: A compound of the formula ##STR1## in which R.sup.1 is hydrogen, lower alkyl, optionally substituted ar(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, protected carboxy)lower)alkyl, carboxy)lower)alkyl, hydroxy(lower)alkyl, optionally substituted lower alkylcarbamoyl(lower)alkyl, lower alkylthio(lower)alkyl, carboxy(lower)alkanoyl, protected carboxy(lower)alkanoyl, aroyl, lower alkanoyl, or optionally substituted arylcarbamoyl(lower)alkyl,R.sup.2 is hydrogen, carboxy, protected carboxy, formyl or N-(lower)alkyl-N-(lower)alkoxycarbamoyl,R.sup.3 is hydrogen or amidino-protective group,A is lower alkylene or carbonyl,X is ##STR2## Y is --S-- or --SO.sub.2 --, Z is --S-- or --O--,or pharmaceutically acceptable salts thereofwhich is useful as a medicament.Type: GrantFiled: March 12, 1999Date of Patent: July 25, 2000Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Akito Tanaka, Hiroaki Mizuno, Minoru Sakurai
-
Patent number: 6084093Abstract: The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: ##STR1## wherein R, R', R.sub.1, R'.sub.1, R.sub.2, R'.sub.2, R.sub.3, R'.sub.3, R.sub.4, R'.sub.4, R.sub.5, R'.sub.5, R.sub.6, R'.sub.6, R.sub.7, R'.sub.7, R.sub.8, R'.sub.8, R.sub.9, and R'.sub.9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.Type: GrantFiled: May 16, 1995Date of Patent: July 4, 2000Assignee: G. D. Searle & Co.Inventors: Dennis P. Riley, Randy H. Weiss, William L. Neuman, Anil S. Modak, Patrick J. Lennon, Karl W. Aston
-
Patent number: 6084098Abstract: Disclosed are compounds of the formula: ##STR1## or pharmaceutically acceptable addition salts thereof wherein: Y represents oxygen or sulfur; Z is nitrogen or CH;R.sub.1, R.sub.2 and R.sub.3 independently represent organic or inorganic substituents;R.sub.4 and R.sub.4 ' independently represent hydrogen, alkyl or form a ring with the atom to which they are attached;R.sub.5 represents hydrogen, alkyl, alkoxy, or alkylthio, and R.sub.6 represents hydrogen or alkyl; or R.sub.5 and R.sub.6 form a ring together with the atoms to which they are attached; andR.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 independently represent hydrogen or alkyl,which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.Type: GrantFiled: February 26, 1999Date of Patent: July 4, 2000Assignee: Neurogen CorporationInventors: Renata Xavier Kover, Silva Terdjanian, Jennifer Tran, Andrew Thurkauf
-
Patent number: 6069114Abstract: Compounds of the formula (I) and their salts ##STR1## in which R.sup.1 to R.sup.6, Y.sup.1, to Y.sup.2, Y.sup.3, m and n are as defined in claim 1 are suitable as herbicides and plant growth regulators. They can be prepared analogously to known processes using intermediates of the formula (V) (cf. claim 6).Type: GrantFiled: February 25, 1997Date of Patent: May 30, 2000Assignee: Hoechst Schering AgrEvo GmbHInventors: Klaus Lorenz, Klemens Minn, Lothar Willms, Klaus Bauer, Hermann Bieringer, Christopher Rosinger
-
Patent number: 6048978Abstract: A process of synthesizing a carbapenem compound of formula 6: ##STR1## is disclosed using a compound of formula 4': ##STR2## The intermediate compounds that are described herein are also included in the present invention.Type: GrantFiled: September 23, 1998Date of Patent: April 11, 2000Assignee: Merck & Co., Inc.Inventors: Mark S. Jensen, Chunhua Yang, Nobuyoshi Yasuda
-
Patent number: 6004961Abstract: The present invention relates to 1,4-disubstituted piperazines of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for the treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.Type: GrantFiled: March 18, 1999Date of Patent: December 21, 1999Assignee: Novo Nordisk A/SInventors: Rolf Hohlweg, Peter Madsen, Tine Krogh J.o slashed.rgensen, Knud Erik Andersen, Brett Watson, Zdenek Polivka, Otylie Konigova, Martina Kovandova, Alexandra Silhankova, Vladimir Valenta
-
Patent number: 6001999Abstract: The invention relates to a compound having the general Formula I in which one of the groups R.sub.1,R.sub.2,R.sub.3,R.sub.4,R.sub.5,R.sub.6 and R.sub.7 represents an ionophoric moiety and the remaining groups each independently are hydrogen, a lipophilic or hydrophilic group or a reactive group for coupling to a polymer or a biomolecule, or R.sub.2 forms an aromatic ring system together with R.sub.3 and R.sub.5 forms an aromatic ring system together with R.sub.6.the compound of the invention is useful as a luminescence indicator for cations.Type: GrantFiled: May 27, 1998Date of Patent: December 14, 1999Assignee: AVL Medical InstrumentsInventors: Otto S. Wolfbeis, Jorg Daub, Thomas Gareis, Matthias Kollmannsberger, Stefan Heinl, Tobias Werner, Christian Huber, Andrei Boila-Gockel, Marco Jean Pierre Leiner
-
Patent number: 5985871Abstract: Compounds having a certain benzoxazine ring system and their precursors are disclosed which are useful for enhancing synaptic responses mediated by AMPA receptors. Also disclosed are methods for preparing such compounds, and methods for their use in treating subjects suffering from impaired nervous or intellectual functioning due to deficiencies in the number of excitatory synapses or in the number of AMPA receptors. The invention compounds can also be used for the treatment of non-impaired subjects for enhancing performance in sensory-motor and cognitive tasks which depend on brain networks utilizing AMPA receptors and for improving memory encoding.Type: GrantFiled: December 24, 1997Date of Patent: November 16, 1999Assignee: Cortex Pharmaceuticals, Inc.Inventors: Gary A. Rogers, Christopher Marrs
-
Patent number: 5972925Abstract: The present invention relates to novel N-substituted amino alcohols, amino acids and acid derivatives thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.Type: GrantFiled: September 4, 1997Date of Patent: October 26, 1999Assignee: Novo Nordisk A/SInventors: Rolf Hohlweg, Tine Krogh J.o slashed.rgensen, Knud Erik Andersen, Uffe Bang Olsen, Peter Madsen, Zdenek Polivka, Otylie Konigova, Frantisek Miksik, Martina Kovandova, Alexandra Silhankova, Karel Sindelar
-
Patent number: 5958782Abstract: A fluorescent ionophoric compound is disclosed that includes a complexing moiety, such as a cryptand or crown-ether portion, and a fluorescing moiety such as a coumarin portion. The coumarin portion may be substituted at the 3-position with an electron withdrawing or polarizable group such as a substituted aromatic group or a substituted heterocyclic group having a heteroatom in at least one of its alpha positions. The compound, which exhibits good photostability, can be incorporated into cation-sensing composite structures by means of convenient points of covalent attachment.Type: GrantFiled: February 27, 1997Date of Patent: September 28, 1999Assignee: Minnesota Mining and Manufacturing CompanyInventors: James G. Bentsen, Shih-Hung Chou, Elisa M. Cross, Kurt J. Halverson, John E. Trend, Cary A. Kipke, Masao Yafuso, Sanjay L. Patil
-
Patent number: 5948906Abstract: The invention discloses fluorescent chelator compounds that are especially useful to monitor and measure cytosolic concentrations of alkali metal cations such as Na.sup.+, K.sup.+, and Li.sup.+. The new compounds are comprised of: (1) crown ethers (that may or may not have substituent groups attached to the core carbons, but will always contain at least one core nitrogen) that are linked via the core nitrogen(s) to at least one (2) fluorophore that contains an additional heteroaromatic liganding center. In the currently preferred dye, SBFI, the core compound is crown ether 1,7-diaza-4,10,13-trioxacyclopentadecane and the heteroaromatic fluorophores are benzofurans that are linked to isophthalate groups. Selectivities for Na.sup.+ over K.sup.+ of about 20 are observed, resulting in effective dissociation constants for Na.sup.+ of about 20 mM against a background of 120 mM K.sup.+. Increasing ?Na.sup.Type: GrantFiled: July 27, 1992Date of Patent: September 7, 1999Assignee: The Regents of the University of CaliforniaInventors: Roger Yonchien Tsien, Akwasi Minta
-
Patent number: 5945423Type: GrantFiled: January 14, 1998Date of Patent: August 31, 1999Assignee: E. I. du Pont de Nemours and CompanyInventors: James Francis Bereznak, Zen-Yu Chang, Thomas Paul Selby, Charlene Gross Sternberg
-
Patent number: 5747481Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.Type: GrantFiled: May 27, 1997Date of Patent: May 5, 1998Assignee: Novo Nordisk A/JInventors: Tine Krough J.o slashed.rgensen, Knud Erik Andersen, Henrik Sune Andersen, Rolf Hohlweg, Peter Madsen, Uffe Bang Olsen
-
Patent number: 5718845Abstract: Nonlinear optical compounds which contain a heteroaromatic ring and may further comprise a tricyanovinyl group attached to the heteroaromatic ring.Type: GrantFiled: January 18, 1995Date of Patent: February 17, 1998Assignee: Enichem S.p.A.Inventors: Kevin J. Drost, Pushkara Rao Varanasi, Kwan-Yue Alex Jen, Michael Anthony Drzewinski
-
Patent number: 5679673Abstract: Certain aralkyl diazabicycloalkyl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychoses and convulsions. Compounds of particular interest are of the formula: ##STR1## wherein each of R, R.sup.1, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 is independently selected from hydrido, lower-alkyl, benzyl, and haloloweralkyl; wherein each of R.sup.2, R.sup.3 and R.sup.10 through R.sup.13 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein each of R.sup.8 and R.sup.Type: GrantFiled: November 21, 1994Date of Patent: October 21, 1997Assignee: The United States of America, represented by the Department of Health and Human ServicesInventors: Wayne Bowen, Brian R. de Costa, Celia Dominguez, Xiao-Shu He, Kenner C. Rice
-
Patent number: 5668127Abstract: Methods, compounds and compositions are provided for inhibiting the growth of pathogenic mycobacteria in vitro and of treatment of pathogenic bacterial infections, such as mycobacterial and clostridium infections, in vivo using bicyclic nitroimidazole compounds of the formula (II): ##STR1## wherein R.sub.1 is hydrogen, halogen, loweralkyl, haloloweralkyl, cycloalkyl, heterocycle, substituted heterocycle and heterocyclicalkyl; X is oxygen, sulfur or NK.sub.2, where R.sub.2 is hydrogen, loweralkyl, aryl, cycloalkyl, heterocycle, substituted heterocycle, heterocyclicalkyl, COR.sub.3 or SO.sub.2 R.sub.4 CONR.sub.4 R.sub.5, where R.sub.4 and R.sub.5 are independently selected from hydrogen, loweralkyl, aryl, alkylaryl, alkoxyalkyl, alkoxyaryl, alkoxyalkoxyaryl, alkylheterocycle, and alkoxyheterocycle; n is 1, 2 or 3; Y and Z are independently selected CH.sub.2, CO, CR.sub.4 R.sub.5 or NR.sub.4, where R.sub.4 and R.sub.Type: GrantFiled: June 26, 1995Date of Patent: September 16, 1997Assignee: PathoGenesis CorporationInventors: William R. Baker, Cai Shaopei, Eric L. Keeler
-
Patent number: 5608058Abstract: A process of preparing a purified crown compound is disclosed which comprises the steps of (a) dissolving a crown compound and a salt in an organic solvent to form a solution of a complex salt of a crown compound; (b) filtering the solution to obtain a filtrate; (c) adding water to the filtrate to produce a precipitate; and (d) filtering out the produced precipitate.Type: GrantFiled: February 1, 1994Date of Patent: March 4, 1997Assignee: Konica CorporationInventors: Shinri Tanaka, Yasuhiko Kawashima
-
Patent number: 5594135Abstract: The present invention relates to a compound of the formula ##STR1## wherein X.sup.1, R.sup.1, R.sup.2, OP, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.0 are as described herein, and their pharmaceutically acceptable salts thereof carrying an acidic and/or basic substituent.The compound of formula I as well as their pharmaceutically acceptable salts inhibit DNA gyrase activity in bacteria and possess antibiotic, especially antibacterial activity against microorganisms and can be used in the control or prevention of infectious diseases.Type: GrantFiled: October 11, 1995Date of Patent: January 14, 1997Assignee: Hoffmann-La Roche Inc.Inventors: J urgen Geiwiz, Erwin G otschi, Paul Hebeisen, Helmut Link, Thomas L ubbers
-
Patent number: 5589473Abstract: The present invention relates to a compound of the formula ##STR1## wherein X.sup.1, R.sup.1, R.sup.2, OP, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.0 are as described herein, and their pharmaceutically acceptable salts thereof carrying an acidic and/or basic substituent.The compound of formula I as well as their pharmaceutically acceptable salts inhibit DNA gyrase activity in bacteria and possess antibiotic, especially antibacterial activity against microorganisms and can be used in the control or prevention of infectious diseases.Type: GrantFiled: March 20, 1995Date of Patent: December 31, 1996Assignee: Hoffmann-La Roche Inc.Inventors: J urgen Geiwiz, Erwin G otschi, Paul Hebeisen, Helmut Link, Thomas L ubbers
-
Patent number: 5580900Abstract: A compound of the formula: ##STR1## in which each R.sup.1 to R.sup.4 group is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkoxy-carbonyl, halo, hydroxy, nitro, cyano, trihalomethyl or optionally substituted phenyl, each R.sup.5 to R.sup.16 group is hydrogen or C.sub.1-4 alkyl, each Z', Z", Z'" and Z"" group is an alkylene radical, and X and Y are each --(CH.sub.2).sub.n -- or --(CH.sub.2).sub.m --A--(CH.sub.2).sub.p -- where A is --CH.dbd.CH--, optionally substituted phenylene or optionally substituted naphthalenyl, n is 2 to 10, and m and p are each 1 or 2, salts thereof, and intermediates for the production thereof.Type: GrantFiled: November 30, 1994Date of Patent: December 3, 1996Assignee: Lilly Industries LimitedInventors: Barry P. Clark, John R. Harris
-
Patent number: 5574158Abstract: A compound of the formula: ##STR1## in which each R.sup.1 to R.sup.4 group is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkoxy-carbonyl, halo, hydroxy, nitro, cyano, trihalomethyl or optionally substituted phenyl, each R.sup.5 to R.sup.16 group is hydrogen or C.sub.1-4 alkyl, each Z', Z", Z'" and Z"" group is an alkylene radical, and X and Y are each --(CH.sub.2).sub.n -- or --(CH.sub.2).sub.m --A--(CH.sub.2).sub.p -- where A is --CH.dbd.CH--, optionally substituted phenylene or optionally substituted naphthalenyl, n is 2 to 10, and m and p are each 1 or 2, salts thereof, and intermediates for the production thereof.Type: GrantFiled: February 20, 1996Date of Patent: November 12, 1996Assignee: Lilly Industries LimitedInventors: Barry P. Clark, John R. Harris
-
Patent number: 5512579Abstract: To provide a compound which exhibits a serotonin antagonism and an acetylcholine release accelerating activity at a well-balanced activity ratio. An aminobenzoic acid derivative represented by the general formula (I) or (II) or a pharmacologically acceptable salt thereof: ##STR1## wherein R.sup.1 represents a group represented by the formula: ##STR2## {wherein A represents a group represented by formula --CH.sub.2 --X--CH.sub.2 -- (wherein X represents O, >N--R.sup.6 or >CHR.sup.7 (wherein R.sup.6 represents lower alkyl and R.sup.7 represents hydrogen or lower alkoxy)), etc.; D and E each represents a group represented by formula --(CH.sub.2).sub.3 --, etc., and R.sup.2 represents lower alkyl. etc.}; R.sup.9 represents alkynyl; R.sup.10 represents amino, etc.; R.sup.11 represents halogen; R.sup.12 and R.sup.13 each represent lower alkyl; a is an integer of 1 to 5; and b is an integer of 0 to 5!.Type: GrantFiled: July 18, 1994Date of Patent: April 30, 1996Assignee: Eisai Co., Ltd.Inventors: Shuhei Miyazawa, Yorohisa Hoshino, Hisashi Shibata, Kazuo Hirota, Takaaki Kameyama, Shinya Abe, Takashi Yamanaka
-
Patent number: 5482936Abstract: Compounds and pharmaceutically acceptable salts thereof formally derived by bridging the 1- and 2-positions of 1H-imidazo[4,5-c]quinolin-4-amines. Also, methods of using such compounds and pharmaceutical formulations containing such compounds. Said compounds are useful to induce interferon biosynthesis in an animal.Type: GrantFiled: January 12, 1995Date of Patent: January 9, 1996Assignee: Minnesota Mining and Manufacturing CompanyInventor: Kyle J. Lindstrom